Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents. Double-blind, placebo-, and active comparator-controlled studies are indicated to rigorously test the efficacy of reboxetine in ADHD.